Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show a fall in quarterly revenue when it reports results on November 7 (estimated) for the period ending June 30 2024
The San Diego California-based company is expected to report a 73.1% decrease in revenue to $104.5 thousand from $388 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of $1.15 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is 13.50, above its last closing price of $5.62.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.12 | -1.10 | -1.19 | Missed | -8 |
Mar. 31 2024 | -1.01 | -1.00 | -1.31 | Missed | -30.6 |
Dec. 31 2023 | -1.42 | -1.27 | -1.12 | Beat | 11.6 |
Jan. 1 0001 | -1.50 | -1.52 | -1.56 | Missed | -2.6 |
Jun. 30 2023 | -1.81 | -1.74 | -1.56 | Beat | 10.3 |
Mar. 31 2023 | -1.76 | -1.74 | -1.92 | Missed | -10.3 |
Dec. 31 2022 | -2.01 | -2.02 | -2.52 | Missed | -25 |
Sep. 30 2022 | -3.56 | -3.55 | -1.80 | Beat | 49.3 |
This summary was machine generated November 6 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。